O-RADS for assessment of adnexal lesions: current status, challenges and future directions

The Ovarian-Adnexal Reporting and Data System (O-RADS), developed by the American College of Radiology (ACR), provides a standardized, evidence-based framework for risk stratification and management of ovarian and adnexal lesions. The O-RADS system is comprised of two complementary imaging arms: ultrasound (US) and magnetic resonance imaging (MRI). O-RADS US serves as the primary imaging modality for adnexal lesion assessment, given its wide availability in outpatient and inpatient settings, relatively low cost, lack of ionizing radiation and the ability for real-time dynamic assessment. Using defined lexicon terms, lesions are stratified into five risk categories corresponding to an estimated malignancy risk with associated management recommendations. Validation studies have demonstrated high sensitivities for malignancy detection, good specificities, and strong interobserver agreement. The 2022 update refined selected descriptors to improve specificity while otherwise maintaining diagnostic performance and reproducibility, reinforcing the system's clinical utility. O-RADS MRI functions as a secondary, problem-solving tool for lesions that are technically limited or when MRI evaluation may add value. Validation studies have consistently shown excellent performance of O-RADS MRI with studies showing high specificities approaching 90-95% related to better characterization of solid tissue based on signal and dynamic enhancement characteristics. Together, O-RADS US and MRI establish a comprehensive, standardized approach that improves diagnostic confidence and optimizes patient management. Ongoing efforts focus on improving congruence between these two arms by addressing discrepancies, understanding and lowering barriers for adoption, and providing management recommendations for O-RADS MRI. Emerging evidence and evolving technologies, such as contrast-enhanced ultrasound (CEUS), quantitative imaging biomarkers and artificial intelligence (AI), may further advance the system. This review summarizes the background and validation of O-RADS US and O-RADS MRI, discusses their complementary roles, current challenges and barriers to adoption, and outlines future priorities and research directions.

Authors

Institutions

Publication Details

Journal
Cancer Imaging
Published
2026-06-27
DOI
https://doi.org/10.1186/s40644-026-01061-5
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

O-RADS for assessment of adnexal lesions: current status, challenges and future directions

Lori M. Strachowski, Elizabeth A. Sadowski, Maitray D. Patel, Rochelle F. Andreotti et al.
Cancer Imaging
Ovarian cancer diagnosis and treatment
article

O-RADS for assessment of adnexal lesions: current status, challenges and future directions

Lori M. Strachowski, Elizabeth A. Sadowski, Maitray D. Patel, Rochelle F. Andreotti, Katherine E. Maturen, Yang Guo, Atul B. Shinagare
article en

Abstract

The Ovarian-Adnexal Reporting and Data System (O-RADS), developed by the American College of Radiology (ACR), provides a standardized, evidence-based framework for risk stratification and management of ovarian and adnexal lesions. The O-RADS system is comprised of two complementary imaging arms: ultrasound (US) and magnetic resonance imaging (MRI). O-RADS US serves as the primary imaging modality for adnexal lesion assessment, given its wide availability in outpatient and inpatient settings, relatively low cost, lack of ionizing radiation and the ability for real-time dynamic assessment. Using defined lexicon terms, lesions are stratified into five risk categories corresponding to an estimated malignancy risk with associated management recommendations. Validation studies have demonstrated high sensitivities for malignancy detection, good specificities, and strong interobserver agreement. The 2022 update refined selected descriptors to improve specificity while otherwise maintaining diagnostic performance and reproducibility, reinforcing the system's clinical utility. O-RADS MRI functions as a secondary, problem-solving tool for lesions that are technically limited or when MRI evaluation may add value. Validation studies have consistently shown excellent performance of O-RADS MRI with studies showing high specificities approaching 90-95% related to better characterization of solid tissue based on signal and dynamic enhancement characteristics. Together, O-RADS US and MRI establish a comprehensive, standardized approach that improves diagnostic confidence and optimizes patient management. Ongoing efforts focus on improving congruence between these two arms by addressing discrepancies, understanding and lowering barriers for adoption, and providing management recommendations for O-RADS MRI. Emerging evidence and evolving technologies, such as contrast-enhanced ultrasound (CEUS), quantitative imaging biomarkers and artificial intelligence (AI), may further advance the system. This review summarizes the background and validation of O-RADS US and O-RADS MRI, discusses their complementary roles, current challenges and barriers to adoption, and outlines future priorities and research directions.

Cancer Imaging
Brigham and Women's Hospital (US), University of Wisconsin–Madison (US), Harvard University (US), University of California, San Francisco (US), University of Michigan (US), WinnMed (US), Michigan Medicine (US), Mayo Clinic in Florida (US), Vanderbilt University Medical Center (US)
Openalex Percentile: Top 6%
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.